文献速递食管与纵隔外科

新辅助放化疗与新辅助化疗治疗食管胃结合部印戒细胞腺癌的结局比较

Outcomes Of Neoadjuvant Chemoradiation Vs Neoadjuvant Chemotherapy for Esophageal Junction Signet Ring Cell Adenocarcinoma.
PubMed 文献 · Ann Thorac Surg · 2026-06-05

该研究比较可切除(I-III期)食管胃结合部印戒细胞腺癌患者接受新辅助放化疗(nCRT)或新辅助化疗(nCT)后手术的结局。

要点

  • nCRT与nCT在可切除GEJ印戒细胞腺癌中生存无显著差异(P=0.28)。
  • nCRT组病理完全缓解率11.5%,nCT组7.7%。
  • 脉管侵犯是进展-free生存和总生存的独立预测因素。

核心结论

  • 印戒细胞癌对治疗抵抗,nCRT或nCT均未能克服这一挑战,需要新治疗策略。

研究设计与样本

  • 两中心回顾性队列研究,纳入2005-2022年接受新辅助治疗后食管切除术的GEJ印戒细胞癌患者,按nCRT或nCT分组,使用倾向评分以2:1匹配,采用Kaplan-Meier和多因素Cox回归分析。

主要发现

  • nCRT组病理完全缓解率11.5%,nCT组7.7%。
  • 中位随访27个月,nCRT组中位生存期34.3个月(95%CI 24.9-72.1),nCT组34.5个月(95%CI 29.0-58.8),P=0.28。
  • 多因素Cox回归显示脉管侵犯是PFS和OS的独立预测因素,而新辅助治疗选择不是。

临床怎么用

  • 对于GEJ印戒细胞腺癌,nCRT和nCT均可作为新辅助治疗选择,但需认识到疗效有限,应关注脉管侵犯等预后因素并探索新策略。

局限性

  • 回顾性研究,样本量有限,可能存在选择偏倚;随访时间较短。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Gastroesophageal junction (GEJ) adenocarcinoma with signet ring cells (SRCs) is associated with resistance to therapy and poor outcomes. Standard neoadjuvant regimens for SRCs have been chemoradiation (nCRT) or chemotherapy (nCT), with little data specific to SRCs indicating which is optimal. We compared outcomes of resectable (stage I-III) GEJ SRC patients treated with nCRT or nCT followed by surgery. METHODS: Patients undergoing esophagectomy for GEJ SRCs after neoadjuvant therapy at 2 different institutions (2005-2022) were stratified by receipt of nCRT or nCT. Propensity scores, based on demographic and clinical characteristics, were used to match groups (2 nCRT:1 nCT). Outcomes were assessed using Kaplan-Meier and multivariable Cox regression models. RESULTS: In sum, 104 (66.7%) nCRT and 52 (33.3%) nCT patients were included. Most patients were male (nCRT, n = 88 of 104, 84.6%; nCT, n = 43 of 52, 82.7%, P = .76) with clinical stage III (nCRT, n = 92 of 104, 88.5%; nCT, n = 48 of 52, 92.3%, P = .33). Patients treated with nCRT achieved pathologic complete response 11.5% vs 7.7% for nCT patients. At median follow-up of 27 months, median survival for nCRT patients was 34.3 months (95% CI, 24.9-72.1) compared with 34.5 months (95% CI, 29.0-58.8; P = 0.28) for nCT patients. Multivariate Cox regression indicated that lymphovascular invasion was an independent predictor of progression-free and overall survival, but choice of neoadjuvant therapy was not. CONCLUSIONS: The treatment-resistant nature of SRCs pose consequential challenges that are not overcome either by nCRT or nCT. Novel therapeutic strategies are needed to improve outcomes for patients with GEJ adenocarcinoma with SRC.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Hooda Z, Langburt D, McCracken A, et al. Outcomes Of Neoadjuvant Chemoradiation Vs Neoadjuvant Chemotherapy for Esophageal Junction Signet Ring Cell Adenocarcinoma. Ann Thorac Surg. 2026. PMID: 42250584. doi:10.1016/j.athoracsur.2026.05.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。